Trial Profile
Pemetrexed Monotherapy for Performance Status 2 Patients in Treatment of Non-Small and Non-Squamous Cell Lung Cancer Patients Without EGFR Mutation.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Sep 2015
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 30 Aug 2012 Planned End Date changed from 1 Feb 2012 to 31 Aug 2014 as reported by University Hospital Medical Information Network - Japan record.
- 21 Oct 2009 New trial record